Skip to content
value.today

NextCure, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to bookPrice to book of Biotechnology: $108 M to $431 M, median $159 M$0 M$116 M$233 M$349 M$465 MMarket value $30 M

Your own DCF model

A full discounted-cash-flow model of NextCure, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times NextCure, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)NextCure, Inc.Applied toValue (25th to 75th)Companies
Price to book3.1× / 4.5× / 12.3×0.9×book equity $35 M$108 M to $431 M70

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025—$-56 M$-50 M———SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024—$-56 M$-41 M$0 M$-41 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023—$-63 M$-53 M$1 M$-54 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022—$-75 M$-54 M$2 M$-56 M$-27 MSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021—$-69 M$-57 M$2 M$-60 M$-12 MSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$22 M$-37 M$-45 M$7 M$-52 M$-29 MSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $30 M on Oct 30, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.